Company profile: PaxMedica
1.1 - Company Overview
Company description
- Provider of biopharmaceutical therapies addressing neurodevelopmental disorders, including PAX-101 for early-stage East African Human African Trypanosomiasis and PAX-101 under development for Autism Spectrum Disorder. Conducts clinical trials evaluating suramin in ASD and collaborates on translational research to support research leading to FDA-approved treatments for autism comorbidities.
Products and services
- Clinical Trials for ASD: PaxMedica conducts clinical-phase studies evaluating suramin’s safety, tolerability, and efficacy in individuals with Autism Spectrum Disorder, generating patient data to inform regulatory pathways
- Partnerships for Translational Research: PaxMedica collaborates with stakeholders to advance FDA-oriented translational research yielding treatments for autism comorbidities, aligning studies and resources toward eventual FDA-approved clinical products
- PAX-101 in ASD: PaxMedica develops investigational-stage PAX-101 to improve independence and quality of life in adolescents and young adults with Autism Spectrum Disorder, targeting improvements in everyday functioning
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to PaxMedica
Quiver Bioscience
HQ: United States
Website
- Description: Provider of human disease models using stem cell and CRISPR engineering for high-throughput screening; proprietary optogenetic electrophysiology and software to measure neuronal activity; AI/ML analytics to decode CNS biology and identify disease phenotypes and candidates; and drug discovery combining single-cell imaging, multi-omics and proprietary engineering to create transformational medicines.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Quiver Bioscience company profile →
Atalanta Therapeutics
HQ: United States
Website
- Description: Provider of biotechnology focused on pioneering new treatment options for neurodegenerative diseases.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Atalanta Therapeutics company profile →
Enspire DBS
HQ: United States
Website
- Description: Provider of deep brain stimulation (DBS) therapy combined with physical rehabilitation to improve arm motor function in stroke recovery patients, including a clinical trial evaluating DBS safety and effectiveness with therapy and a weekly rehabilitation program as part of the trial.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Enspire DBS company profile →
Arthex Biotech
HQ: Spain
Website
- Description: Provider of antisense RNA and anti-miR therapies for Myotonic Dystrophy, including a program targeting upregulated miRNA to address the disease’s root cause and improve delivery to muscle tissue, and early preclinical development of an innovative Type 1 Myotonic Dystrophy drug with in vitro toxicity and preliminary pharmacokinetic and pharmacodynamic studies.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Arthex Biotech company profile →
Cerus Endovascular
HQ: United Kingdom
Website
- Description: Provider of interventional neuroradiology devices and delivery systems, including the e-clipse aneurysm occlusive device that addresses neurovascular aneurysm procedures currently attempted by surgical clipping, minimally invasive metal coils, and liquid embolics.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Cerus Endovascular company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for PaxMedica
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to PaxMedica
2.2 - Growth funds investing in similar companies to PaxMedica
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for PaxMedica
4.2 - Public trading comparable groups for PaxMedica
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →